Cardio-Oncology

Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy Transforming VTE Care: From Risk Identification to Protocol Implementation What is VTE: Why Does it Matter? HIF1α Attenuates Doxorubicin‐Induced Cardiotoxicity by Activating TEX264‐Associated ER‐phagy Researchers at Heart Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities Cardio‐Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies Response by Omland et al to Letter Regarding Article, “Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial” Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191 Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191